- Projects & figures
- News & Events
- Managing your project
- About ERC
Spacecraft follow the same tendency as our computers to become continuously smaller, but more connected. In his ERC grant “NetSat”, Klaus Schilling, from the Zentrum für Telematik in Würzburg, studies control strategies for small pico-satellites in formation, in order to achieve the best performance through their cooperation.
The deep seafloor covers around 70% of our planet’s surface and is home to a diverse community of microorganisms, mostly bacteria. These single-cell life forms inhabit some of the most extreme places in the world, with freezing waters, permanent darkness, high pressure and little food. ERC grantee Antje Boetius studies these microbes in the abyss and their important role for the Earth’s nutrient cycles.
Applied theatre tells a story not for the purposes of entertainment but for social, economic, political or therapeutic reasons. Prof. Matthias Warstat, funded by the ERC, wants to know more about the growth and impact of this form of theatre across the world.
Will spacecraft follow a similar evolution to computers? While information processing in the last century was performed by large mainframe computers, today, networked smart phones dominate the market. In spacecraft engineering a similar paradigm shift is apparent: from traditional single, large, and multifunctional satellites towards groups of very small satellites that cooperate together. Professor Klaus Schilling, in his ERC project “NetSat”, addresses crucial challenges to enable small satellite formations to self-organise. This offers innovative application perspectives in areas like Earth observation, science exploration or telecommunications.
How do proteins trigger complex signal processing tasks, such as neurotransmission, in cells? Thanks to the development of innovative molecular simulation techniques, this ERC-funded project has brought new insights into the transmission of messages inside and between cells.
The use and misuse of antibiotics has accelerated the emergence of drug-resistant bacterial strains, threatening our ability to treat common diseases. EU-funded research has shed new light on the mechanisms behind these microbial mutations, with implications for our understanding of diseases and resistance to treatment.
Maria Brandão de Vasconcelos, together with her colleague Filipa Matos Baptista, Henrique Veiga-Fernandes (ERC grantee), Diogo Fonseca Pereira and Sílvia Arroz Madeira, founded StemCell2MAX in 2015. The company is a biotechnology start-up, specialised in cell based therapies, including novel solutions to multiply the scarcely available blood stem cells, addressing an enormous demand for research and cancer treatment. StemCell2MAX technology is based on Prof. Veiga-Fernandes's ground-breaking discoveries in hematopoietic stem cell biology.
Originally published in March 2017 as part of the multimedia campaign "ERC - 10 years – 10 portraits."
Haematopoietic Stem Cells (HSCs) are blood cells located in the bone marrow. These cells are extensively used in research to develop treatments for many severe diseases, including HIV and multiple sclerosis, and their transplant is a key therapy for certain types of cancer like leukemia and multiple myeloma. However, the use of HSCs is seriously constrained by their limited availability since growing them in the lab does not produce very large quantities. There is therefore an urgent need for methods allowing scientists to multiply HSCs, without losing any of their properties.
Prof. Ian Thomas Baldwin received an ERC Advanced Grant to study the internal circadian clock of plants. In particular, he wants to understand the ecological consequences of plants fallings ‘out of synch’. In this interview, Prof. Baldwin shares some of his research findings and explains why he has chosen to make his study results openly available.
With her degree in biology, Dr Maria-Elena Torres-Padilla left Mexico and embarked on an international career in epigenetics. She completed her PhD at the Pasteur Institute in Paris and then moved to Cambridge University. In 2006 she joined IGBMC in Strasbourg working as a group leader. She has just been appointed Director of the Institute of Epigenetics and Stem Cells of the Helmholtz Zentrum in Munich. Supported by an ERC grant, she studies the mechanisms controlling embryonic cellular plasticity with the aim of shedding new light on today's fertility issues. In this interview she shares her story as a non-European scientist in Europe.